Supernus Pharmaceuticals, Inc. (SUPN)

Market Cap	1.98B
Revenue (ttm)	667.24M
Net Income (ttm)	60.71M
Shares Out	54.38M
EPS (ttm)	1.04
PE Ratio	34.99
Forward PE	20.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	251,004
Open	36.20
Previous Close	36.40
Day's Range	34.37 - 36.59
52-Week Range	24.95 - 42.09
Beta	1.01
Analysts	Buy
Price Target	43.61 (+19.84%)
Earnings Date	May 8, 2023

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 1, 2012
• Employees: 575
• Stock Exchange: NASDAQ
• Ticker Symbol: SUPN

Financial Performance

In 2022, SUPN's revenue was $667.24 million, an increase of 15.09% compared to the previous year's $579.78 million. Earnings were $60.71 million, an increase of 13.64%.

Analyst Forecast

According to 10 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is $43.61, which is an increase of 19.84% from the latest price.

Price Target

$43.61

(19.84% upside)

Analyst Consensus: Buy